Michael Sopt, MD
Family Medicine · Bethlehem, GANPI 1518905827
Payments from drug & device makers
Across 542 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Pfizer$1K
- AbbVie$883
- Novo Nordisk$720
- AstraZeneca$653
- Takeda Pharmaceuticals U.S.A., Inc.$485
- plus $4K from 30 others
What the payments were for
- Food & beverage$8,908100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 76 | $1,164 |
| Pfizer | 60 | $1,030 |
| AbbVie(2 entities) | 62 | $883 |
| Novo Nordisk | 53 | $720 |
| AstraZeneca | 36 | $653 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $485 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $436 |
| Amgen(2 entities) | 23 | $433 |
| Boehringer Ingelheim | 24 | $425 |
| Exact Sciences | 13 | $256 |
| Abbott | 12 | $255 |
| Amarin Pharma, Inc. | 15 | $226 |
| Johnson & Johnson | 11 | $215 |
| Bayer | 10 | $212 |
| GSK | 11 | $189 |
| Sanofi-aventis U.S. LLC | 10 | $186 |
| Dexcom, Inc. | 7 | $145 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $145 |
| Edwards Lifesciences | 5 | $141 |
| Merck | 6 | $101 |
| Biohaven Pharmaceuticals, Inc. | 6 | $100 |
| Novartis | 4 | $80 |
| Idorsia Pharmaceuticals US Inc | 4 | $53 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $51 |
| Supernus Pharmaceuticals, Inc. | 3 | $49 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Phathom Pharmaceuticals, Inc. | 3 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Axsome Therapeutics, Inc. | 2 | $26 |
| IBSA Pharma Inc. | 2 | $26 |
| Corcept Therapeutics | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $19 |
| Nevro Corp. | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Boston Scientific | 1 | $15 |
How this compares
$8,908 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 111 | $206,988 |
| JardianceEmpagliflozin | 106 | $171,325 |
| TrulicityDulaglutide | 100 | $141,775 |
| EliquisApixaban | 81 | $83,532 |
| MounjaroTirzepatide | 58 | $79,433 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $49,229 |
| Dupixent SyringeDupilumab | 12 | $45,876 |
| FarxigaDapagliflozin Propanediol | 37 | $40,149 |
| JanuviaSitagliptin Phosphate | 20 | $29,456 |
| Nurtec OdtRimegepant Sulfate | 21 | $26,732 |
| RybelsusSemaglutide | 11 | $26,044 |
| ProliaDenosumab | 15 | $25,861 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $25,133 |
| XareltoRivaroxaban | 20 | $18,867 |
| Emgality PenGalcanezumab-Gnlm | 15 | $14,709 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $720 | $233,032122 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,164 | $221,207158 claims |
| Boehringer IngelheimJardiance, Glyxambi | $425 | $184,491119 claims |
| PfizerEliquis, Nurtec Odt | $1,030 | $110,265102 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $189 | $63,17363 claims |
| AstraZenecaFarxiga, Brilinta | $653 | $46,73450 claims |
| MerckJanuvia, Janumet Xr | $101 | $38,44435 claims |
| AmgenProlia | $433 | $25,86115 claims |
| Johnson & JohnsonXarelto | $215 | $18,86720 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $186 | $12,86113 claims |
| AbbVieSynthroid | $883 | $2,85723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Bethlehem
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.